Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

NHS-IL12 Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04303117
Recruitment Status : Recruiting
First Posted : March 10, 2020
Last Update Posted : June 24, 2022
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) )

Brief Summary:


Kaposi sarcoma (KS) tumors grow on the skin, lymph nodes, lungs, bone, and gastrointestinal tract. KS often affects people with immune deficiencies, such as among people living with HIV or those with prior history of transplant. Researchers want to see if 2 non-chemotherapy drugs can help people with KS. NHS-IL12 triggers the immune system to fight tumors. M7824 blocks the pathways that cancer cells use to stop the immune system from fighting tumors.


To learn if giving NHS-IL12 alone or with M7824 could help the immune system fight KS tumors.


People 18 and older with KS that has been treated with chemotherapy or immunotherapy


Participants will be screened with some or all of the following:

medical history

physical exam

chest X-ray

computed tomography scan

blood and urine tests

electrocardiogram and echocardiogram

skin KS lesion biopsy

lung exam

gastrointestinal exam

All participants will get NHS-IL12 every 4 weeks for up to 96 weeks (or 24cycles). It is injected under the skin.

Some participants will also get M7824 every 2 weeks for up to 96 weeks (or 24cycles). It is given through a plastic tube that is put in an arm vein.

Participants will complete questionnaires about how KS affects their quality of life. Their KS lesions will be measured and photographed. They will repeat some of the screening tests. They will give saliva samples or additional tissue samples. They will have a lung function test. Their ability to perform their normal activities will be assessed. The treatment duration is up to 96 weeks (or 24cycles) with an option to take NHS-IL12 and/or M7824 until the KS tumors are not responding, or you develop unacceptable side effects.

Participants will have follow-up visits 7 and 30 days after treatment ends, then every 3 to 6 months for the next 18 months, then once a year for 3 years.

Condition or disease Intervention/treatment Phase
Kaposi Sarcoma Drug: NHS-IL12 Drug: M7824 Phase 1 Phase 2

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 64 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I/II of NHS-IL12 Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma
Actual Study Start Date : July 13, 2020
Estimated Primary Completion Date : September 1, 2025
Estimated Study Completion Date : December 1, 2025

Arm Intervention/treatment
Experimental: Arm 1/Monotherapy
Treatment with NHS-IL12 at de-escalating doses if necessary
Drug: NHS-IL12
An initial dose of 16.8 mcg/kg administered subcutaneously every 4 weeks and at an MTD dose with M7824 on day 1 of a 28-day cycle.

Experimental: Arm 1a/Monotherapy Expansion
Treatment with NHS-IL12 at MTD
Drug: NHS-IL12
An initial dose of 16.8 mcg/kg administered subcutaneously every 4 weeks and at an MTD dose with M7824 on day 1 of a 28-day cycle.

Experimental: Arm 2/Combination therapy
Treatment with NHS-IL12 at MTD and M7824 at a fixed dose
Drug: NHS-IL12
An initial dose of 16.8 mcg/kg administered subcutaneously every 4 weeks and at an MTD dose with M7824 on day 1 of a 28-day cycle.

Drug: M7824
1200 mg administered IV every two weeks while on NHS-IL12.

Primary Outcome Measures :
  1. safety, tolerability and activity of NHS-IL12 alone or in combination with M7824 [ Time Frame: 24 cycles of treatment, until confirmed progression, unacceptable toxicity or trial withdrawal ]
    The fraction of participants with toxicity noted at each dose level will be reported by grade and type of toxicity identified. Maximum tolerated dose will also be reported.

Secondary Outcome Measures :
  1. progression free survival [ Time Frame: every 3 months for the first 6 months after completion of therapy, then every six months for the next 18 months, and then annually for a total of 3 years ]
    duration of time from the start of the treatment until time of disease relapse from PR, disease progression, or death, whichever occurs first

  2. objective response rates [ Time Frame: every 3 months for the first 6 months after completion of therapy, then every six months for the next 18 months, and then annually for a total of 3 years ]
    Percentage of participants with the best overall response of CR or PR to therapy

  3. duration of response [ Time Frame: every 3 months for the first 6 months after completion of therapy, then every six months for the next 18 months, and then annually for a total of 3 years ]
    the time criteria are met for CR or PR (whichever is recorded first) until the first date that participant no longer qualifies as a PR

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
  • Participants with biopsy proven (confirmed in the Laboratory of Pathology, CCR) Kaposi sarcoma (KS)
  • KS requiring systemic therapy, with a history of prior therapy:

    • T1 KS or T0 KS sufficiently widespread that systemic therapy is advisable, or KS affecting quality-of-life due to local symptoms or psychological distress


  • KS participants with an inadequate response to liposomal doxorubicin, paclitaxel, other systemic chemotherapy (either progressive disease or stable disease after 3 or more cycles) or immunotherapy (progressive disease)

    • A wash-out period off treatment of 2 weeks from last chemotherapy and 4 weeks from last immunotherapy, other systemic treatment with a biologic agent, or monoclonal antibody therapy will be required.
    • Resolution of toxicity from prior therapy to less than or equal to Grade 1.
    • At least five measurable cutaneous KS lesions with no previous local radiation, surgical or intralesional cytotoxic therapy that would prevent response assessment for that lesion.
    • Measurable disease by the criteria proposed by the AIDS Clinical Trials Group (ACTG) Oncology Committee for KS
    • Participants can be HIV positive or negative.
    • ART for HIV+ participants for 8 or more weeks prior to entry with an HIV viral load of <400 copies/ml at screening and CD4+ T cell count of >= 50 cells/microliter as this may be expected if participants have received several courses of chemotherapy.
    • Age greater than or equal to18 years.
    • ECOG performance status less than or equal to 2 (Karnofsky greater than or equal to 60%).
    • Participants must have adequate organ and marrow function as defined below:
  • absolute neutrophil count greater than or equal to 1,500/mcL
  • platelets greater than or equal to 100,000/mcL
  • total bilirubin within normal institutional limits; OR <3x institutional ULN for Gilbert s syndrome or HIV protease inhibitors; OR <5x ULN and direct bilirubin < 0.7mg/dL for participants on atazanavir-containing HIV regimen
  • AST(SGOT)/ALT(SGPT) less than or equal to 1.5 X institutional upper limit of normal
  • hemoglobin greater than or equal to 9g/dL
  • Creatinine within normal institutional limits OR creatinine clearance >30 mL/min/1.73m^2 as estimated by either Cockroft-Gault of 24- hour urine collection for participants with creatinine levels above institutional normal

    • Normal international normaoized ration (INR), PT less than or equal to 1.5 x ULN and activated partial thromboplastin time (aPTT) less than or equal to 1.5 x ULN
    • The effects of NHS-IL12 and M7824 on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, during treatment and for at least 4 months after the last dose of treatment and agree to inform the treating physician immediately if they become pregnant. Also, there is unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with M7824 and/or NHS-IL12, therefore female participants must agree to discontinue breastfeeding if treated with these agents.
    • Ability of subject to understand and the willingness to sign a written informed consent document.


  • Participants who are receiving any other investigational agents.
  • Pregnant women are excluded from this study as the effects of NHS-IL12 and M7824 have potential teratogenic or abortifacient effects.
  • Severe KS (such as symptomatic pulmonary KS) that could be life threatening if it progressed over 2-4 weeks
  • Actively bleeding sites caused by visceral KS.
  • Subjects unwilling to accept blood products as medically indicated
  • Participants who are actively bleeding and/or requiring transfusions in the 2 weeks preceding study entry.
  • Participants with history of bleeding, diathesis, or recent major bleeding events within a period of 4 weeks considered by the investigator as high risk for investigational drug treatment.
  • Participants with any active or recent history (symptomatic in the last 3 months) of a known or suspected autoimmune disease (with the exception of diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid diseases not requiring immunosuppressive treatment) or recent history of a syndrome that required systemic corticosteroids (10mg daily prednisone or equivalent) or immunosuppressive medications except inhaled steroids and adrenal replacement steroids doses up to 10mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.Uncontrolled opportunistic infections
  • Active multicentric Castleman disease
  • Participants with primary effusion lymphoma
  • History of malignant tumors other than KS, unless:

    • In complete remission for greater than or equal to 3 years from the time complete remission was first documented or
    • Resected basal cell or squamous cell carcinoma of the skin or
    • In situ cervical or anal dysplasia
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to NHS-IL12 and/or M7824 investigational agents used in study.
  • Active tuberculosis (TB):

    • Participants who are undergoing first month of therapy (RIPE or equivalent) for active TB or
    • Participants with TB immune reconstitution syndrome (IRIS) requiring corticosteroids
  • Participants who have received or will receive a live vaccine within 30 days prior to the first administration of study intervention. Seasonal flu vaccines that do not contain a live virus are permitted. Locally approved COVID vaccines are permitted.
  • Uncontrolled substantial intercurrent illness including, but not limited to, ongoing or active severe infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, that would limit compliance with study requirements.
  • Medical or psychiatric illness or social situation that would, in the opinion of the investigator, preclude participation in the study or the ability of participants to provide informed consent for themselves.
  • Uncontrolled HBV infection, defined as plasma HBV DNA detectable by PCR

Note: the following will NOT be exclusionary:

  • A positive hepatitis B serology indicative of previous immunization (i.e. HBsAb positive and HBcAb negative), or a fully resolved acute HBV infection
  • Participants with chronic HBV suppressed by appropriate antiretroviral therapy with activity against HBV, as outlined in DHHS guidelines.

    • Uncontrolled HCV infection, defined as plasma HCV DNA detectable by PCR

Note: the following will NOT be exclusionary:

  • Positive HCV serology but no detectable HCV RNA, indicative of spontaneously cleared HCV infection
  • Participants who have been successfully treated for HCV as long as therapy for HCV has been completed.

    -Participants will be excluded from the combination therapy arm if:

  • they have discontinued prior PD1/L1 blocking agent due to immune mediated adverse event(s) OR
  • they have active non-infectious pneumonitis or a history of steroid requiring non-infectious pneumonitis.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04303117

Layout table for location contacts
Contact: Irene Ekwede, R.N. (240) 760-6126
Contact: Ramya M Ramaswami, M.D. (240) 506-1088

Layout table for location information
United States, Maryland
National Institutes of Health Clinical Center Recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office    888-624-1937      
Sponsors and Collaborators
National Cancer Institute (NCI)
Layout table for investigator information
Principal Investigator: Ramya M Ramaswami, M.D. National Cancer Institute (NCI)
Additional Information:
Layout table for additonal information
Responsible Party: National Cancer Institute (NCI) Identifier: NCT04303117    
Other Study ID Numbers: 200061
First Posted: March 10, 2020    Key Record Dates
Last Update Posted: June 24, 2022
Last Verified: May 11, 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: .All IPD recorded in the medical record will be shared with intramural investigators upon request.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Time Frame: Clinical data available during the study and indefinitely.
Access Criteria: Clinical data will be made available via subscription to BTRIS and with the permission of the study PI

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) ):
Immune Therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Sarcoma, Kaposi
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Herpesviridae Infections
DNA Virus Infections
Virus Diseases
Neoplasms, Vascular Tissue